Aprea Therapeutics, Inc. announced on October 15 2025 that it has determined the recommended Phase 2 dose (RP2D) of 1,100 mg once daily for its oral ATR inhibitor ATRN‑119. The RP2D was established in the monotherapy arm of the ongoing ABOYA‑119 Phase 1/2a dose‑escalation study enrolling patients with advanced solid tumors.
The company’s announcement notes that enrollment in both the once‑daily and twice‑daily monotherapy arms of ABOYA‑119 has been paused, while patients already receiving ATRN‑119 will continue therapy without interruption. This milestone marks a critical step toward advancing ATRN‑119 into the next stage of clinical development and provides a clear dosing target for future studies.
Aprea is exploring combination strategies that could expand ATRN‑119’s therapeutic potential, including co‑administration with DNA‑damaging agents, radiation therapy, immune‑checkpoint inhibitors, and antibody‑drug conjugates. Discussions are underway with leading academic centers to evaluate ATRN‑119 in combination with radiation for HPV‑positive head and neck cancer, a setting where preclinical data suggest synergistic anti‑tumor effects.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.